As scientific capacity expands throughout the world, the International AIDS Vaccine Initiative (IAVI) works with governments and other partners to identify, strengthen and harness capacities to advance AIDS vaccine research and development (R&D), particularly in innovative developing countries such as Brazil.
This study, a collaboration between IAVI, the Brazilian Association of Collective Health, and the Brazilian Department of STD, AIDS and Viral Hepatitis, explores how targeted policy reforms focusing on collaboration, product development capacity, and financing and regulatory coordination could accelerate Brazil’s participation in AIDS vaccine R&D.
The study identified the following key obstacles to advancing AIDS Vaccine R&D in Brazil:
Mechanisms for coordination and collaboration are insufficient. Product development capacity is limited. AIDS vaccines are inadequately prioritized and coordinated across financing mechanisms. Insufficient administrative support and communications weaken the regulatory system. Resultant key recommendations for improving Brazil’s biopharmaceutical capacity are as follows: Map Brazil’s AIDS vaccine technical capacities and scientific expertise to identify priorities for investment. Form multi-sector research networks and working groups. Stimulate innovation through public investment in public and private producers. Develop a comprehensive plan for prioritizing AIDS vaccine R&D across existing financing mechanisms. Enhance administrative support and catalogue and disseminate regulatory and importation requirements.
To learn more about this study undertaken by IAVI, read Enhancing Brazil’s Capacity for Biopharmaceutical Innovation
Brazilian Association of Collective Health (ABRASCO) http://www.abrasco.org.br/
Brazilian Department of STD, AIDS and Viral Hepatitis http://www.aids.gov.br